Avita Medical Earnings Call Signals Stabilizing Growth

Avita Medical Ltd ((RCEL)) has held its Q4 earnings call. Read on for the main highlights of the call.

Avita Medical’s latest earnings call painted a cautious but constructive picture, with 2025 framed as a year of stabilization and execution discipline rather than breakout growth. Management emphasized steady revenue expansion, tighter cost control, improved cash usage, and a de-risked balance sheet, even as margin compression, Q4 softness, and ongoing reimbursement gaps kept profitability firmly in the distance.

Full-Year Growth Amid a Stabilizing Top Line

Avita reported 2025 revenue of about $71.6 million, up roughly 11% from 2024 and marking a second consecutive year of top-line growth. Management stressed that this performance underscores enduring demand for its burn and wound-care platform, even though the year was more about operational reset than rapid acceleration.

2026 Revenue Outlook Anchored in ReCell and New Products

For 2026, the company guided revenue to a range of $80.0–$85.0 million, implying approximately 12%–19% growth over 2025. The outlook assumes a normalization of ReCell utilization as reimbursement uncertainties fade, plus incremental contributions from newer offerings CoHiliX and PermeDerm.

High Gross Margins Provide Strategic Cushion

Despite pressure, Avita maintained a high-margin profile, with full-year gross margin at 82.1% and Q4 at 81.2%. Management positioned this >80% margin band as a strategic buffer that supports investment in growth initiatives, even as product mix and inventory charges weighed on year-on-year comparisons.

Operating Cost Discipline Begins to Take Hold

Full-year operating expenses fell by $10.4 million, a decline of roughly 9% versus 2024, signaling a shift to a leaner model. In Q4, OpEx came in at $24.7 million, down 5% year over year, and excluding $1.2 million in one-time severance, quarterly OpEx was down close to 10%.

Cash Burn Trends Improve and Liquidity Strengthens

Net cash use improved over three consecutive quarters, tightening from $10.1 million in Q2 to $6.2 million in Q3 and $5.1 million in Q4. Avita ended the year with $18.2 million in cash and marketable securities, giving the company a modest but improving liquidity runway.

Refinanced Credit Facility Reduces Covenant Pressure

In January, Avita refinanced its debt with a new facility from Perceptive Advisors that materially lowered covenant risk. The agreement cuts the minimum cash requirement to $5.0 million, sets revenue covenants well below 2026 guidance, and offers an interest-only structure with optional additional capital.

Reimbursement Clarity Returns Across Most U.S. Regions

Six of seven Medicare Administrative Contractors have now published payment rates for ReCell procedures, removing a key overhang that had limited utilization. Management said this clarity is already leading to early signs of normalization and reengagement from hospital accounts previously on the sidelines.

Advancing a Multi-Product Platform Strategy

Avita highlighted clinical and commercial progress across its broader platform, positioning CoHiliX and PermeDerm as important future growth drivers. The CoHiliX I post-market study is fully enrolled, PERMEADERM-one is nearing full enrollment with data expected later in 2026, and a CE Mark for ReCell Go has enabled initial European use.

Focus Shifts to Organic Utilization in Core Centers

Commercial strategy is pivoting toward driving organic monthly use across roughly 200 core burn and trauma centers that represent about 90% of revenue. The company is moving away from bulk ordering patterns in favor of recurring utilization, aiming for more predictable demand and deeper account penetration.

Q4 Revenue Softness Underscores Slow Acceleration

Fourth-quarter 2025 revenue slipped to $17.6 million from $18.4 million a year earlier, a decline of roughly 4.3%. Management characterized the period as one of stabilization rather than growth, reflecting lingering reimbursement disruption and the transition toward new utilization patterns.

Margin Compression Reflects Inventory and Product Mix

Gross margin contracted from 85.8% in 2024 to 82.1% in 2025, with Q4 margins falling from 87.6% to 81.2%. The company cited inventory reserves and a mix shift toward newer products like CoHiliX and PermeDerm, which add gross profit but currently dilute margin percentages.

Operating Costs Still Outpace Revenue in the Near Term

Despite cost reductions, Avita remains structurally unprofitable, with Q4 operating expenses of $24.7 million exceeding revenue of $17.6 million. Management acknowledged that more scale and continued expense discipline are needed before the business can approach break-even.

Reimbursement Drag and Remaining MAC Uncertainty

Reimbursement turbulence across 2025 weighed on ReCell utilization, and one Medicare Administrative Contractor has yet to publish rates. This remaining gap could delay full normalization in affected regions, leaving some uncertainty around the pace of utilization recovery.

Inventory Reserves and New Products Pressure Reported Margins

Inventory reserves taken during 2025 and a growing contribution from CoHiliX and PermeDerm further compressed headline gross margin. Management argued that these newer products add incremental gross profit without proportional operating cost increases, suggesting underlying economic value is stronger than the percentage margin implies.

One-Time Severance Costs Distort Q4 Expense View

The company incurred $1.2 million of nonrecurring severance in Q4, briefly elevating reported operating expenses. Adjusting for this charge shows a sharper underlying decline in quarterly OpEx, reinforcing the narrative of tightening cost control.

Guidance Signals Execution-Led Growth in 2026

Looking ahead, Avita expects 2026 revenue of $80–$85 million, or about 12%–19% growth, driven by normalized ReCell usage and increasing traction of CoHiliX and PermeDerm within its ~200 core centers. The company is backing this outlook with ongoing cost discipline, improved cash burn trends, more forgiving credit covenants, and steadily improving reimbursement clarity.

Avita’s earnings call left investors with a picture of a company that has lowered its execution and balance-sheet risk while still wrestling with margin and profitability challenges. If reimbursement fully normalizes and the multi-product strategy gains traction, 2026 could mark the transition from mere stabilization to more durable, execution-led growth.